These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 24735732)

  • 1. PI3K inhibitors as potential therapeutics for autoimmune disease.
    Ball J; Archer S; Ward S
    Drug Discov Today; 2014 Aug; 19(8):1195-9. PubMed ID: 24735732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of PI3K Isoforms in Autoimmune Disease.
    Ward SG
    Curr Top Microbiol Immunol; 2022; 436():337-347. PubMed ID: 36243851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PI3K signaling spurs new therapeutic opportunities in inflammatory/autoimmune diseases and hematological malignancies.
    Foster JG; Blunt MD; Carter E; Ward SG
    Pharmacol Rev; 2012 Oct; 64(4):1027-54. PubMed ID: 23023033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of phosphoinositide 3-kinase inhibitors.
    Ward S; Sotsios Y; Dowden J; Bruce I; Finan P
    Chem Biol; 2003 Mar; 10(3):207-13. PubMed ID: 12670534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3 kinase inhibitors in the clinic: an update.
    Kurtz JE; Ray-Coquard I
    Anticancer Res; 2012 Jul; 32(7):2463-70. PubMed ID: 22753702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents.
    Ward SG; Finan P
    Curr Opin Pharmacol; 2003 Aug; 3(4):426-34. PubMed ID: 12901953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K inhibitors in cardiovascular disease.
    Eisenreich A; Rauch U
    Cardiovasc Ther; 2011 Feb; 29(1):29-36. PubMed ID: 20626398
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K inhibitors in inflammation, autoimmunity and cancer.
    Stark AK; Sriskantharajah S; Hessel EM; Okkenhaug K
    Curr Opin Pharmacol; 2015 Aug; 23():82-91. PubMed ID: 26093105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic applications of PI3K inhibitors in cardiovascular diseases.
    Ghigo A; Morello F; Perino A; Hirsch E
    Future Med Chem; 2013 Mar; 5(4):479-92. PubMed ID: 23495693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective and potent small-molecule inhibitors of PI3Ks.
    Jeong Y; Kwon D; Hong S
    Future Med Chem; 2014 May; 6(7):737-56. PubMed ID: 24941870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease.
    Venable JD; Ameriks MK; Blevitt JM; Thurmond RL; Fung-Leung WP
    Recent Pat Inflamm Allergy Drug Discov; 2010 Jan; 4(1):1-15. PubMed ID: 20017720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511.
    Norman MH; Andrews KL; Bo YY; Booker SK; Caenepeel S; Cee VJ; D'Angelo ND; Freeman DJ; Herberich BJ; Hong FT; Jackson CL; Jiang J; Lanman BA; Liu L; McCarter JD; Mullady EL; Nishimura N; Pettus LH; Reed AB; Miguel TS; Smith AL; Stec MM; Tadesse S; Tasker A; Aidasani D; Zhu X; Subramanian R; Tamayo NA; Wang L; Whittington DA; Wu B; Wu T; Wurz RP; Yang K; Zalameda L; Zhang N; Hughes PE
    J Med Chem; 2012 Sep; 55(17):7796-816. PubMed ID: 22897589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods to measure the enzymatic activity of PI3Ks.
    Ciraolo E; Gulluni F; Hirsch E
    Methods Enzymol; 2014; 543():115-40. PubMed ID: 24924130
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterocyclic compounds and their uses: a patent evaluation of WO2010151735A2.
    Scozzafava A; Supuran CT
    Expert Opin Ther Pat; 2011 May; 21(5):803-6. PubMed ID: 21434841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of highly potent and selective PI3Kδ inhibitors.
    Marcoux D; Qin LY; Ruan Z; Shi Q; Ruan Q; Weigelt C; Qiu H; Schieven G; Hynes J; Bhide R; Poss M; Tino J
    Bioorg Med Chem Lett; 2017 Jul; 27(13):2849-2853. PubMed ID: 28209465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective pharmacological inhibition of phosphoinositide 3-kinase p110delta opposes the progression of autoimmune diabetes in non-obese diabetic (NOD) mice.
    Durand CA; Richer MJ; Brenker K; Graves M; Shanina I; Choi K; Horwitz MS; Puri KD; Gold MR
    Autoimmunity; 2013 Feb; 46(1):62-73. PubMed ID: 23039284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phosphoinositide 3-kinases in health and disease.
    Ghigo A; Morello F; Perino A; Hirsch E
    Subcell Biochem; 2012; 58():183-213. PubMed ID: 22403077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K Signaling in Chronic Obstructive Pulmonary Disease: Mechanisms, Targets, and Therapy.
    Pirozzi F; Ren K; Murabito A; Ghigo A
    Curr Med Chem; 2019; 26(16):2791-2800. PubMed ID: 29557740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor.
    Mallon R; Feldberg LR; Lucas J; Chaudhary I; Dehnhardt C; Santos ED; Chen Z; dos Santos O; Ayral-Kaloustian S; Venkatesan A; Hollander I
    Clin Cancer Res; 2011 May; 17(10):3193-203. PubMed ID: 21325073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pathophysiological roles of PI3Ks and therapeutic potential of selective inhibitors in allergic inflammation.
    Takeda M; Ito W; Tanabe M; Ueki S; Kihara J; Kato H; Tanigai T; Kayaba H; Sasaki T; Chihara J
    Int Arch Allergy Immunol; 2010; 152 Suppl 1():90-5. PubMed ID: 20523070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.